Rheumatoid Arthritis Drug May Help Treat Inflammation In Stroke Patients

Rheumatoid Arthritis Drug May Help Treat Inflammation In Stroke Patients

by Rishika Gupta on  March 28, 2018 at 11:53 AM Health Watch
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights
  • Kineret, an anti-inflammatory drug could help reduce inflammation in strokes.
  • Kineret works by blocking the actions of Interleukin-1 (IL-1), which is released as a response stroke.
  • Kineret has been clinically licensed for treating rheumatoid arthritis.
Kineret, an anti-inflammatory drug when given to patients in the early stages of a stroke say within six hours can help reduce the level of inflammation in them, finds a new study. The findings of this study are published in the journal of Stroke.
Rheumatoid Arthritis Drug May Help Treat Inflammation In Stroke Patients

Kineret has been officially licensed to treat rheumatoid arthritis. In the study, it was given as a small injection just under the skin without giving the patients any identifiable adverse reactions.

Interleukin-1 protein- the main component

Interleukin-1 protein is produced naturally and is the part of body's defense to combat a range of illnesses.

In a previous study, the scientists at the University of Manchester have shown that IL-1 tends to increase inflammation and brain injury after a stroke.

How Kineret works?

The anti-inflammatory drug, Kineret works by blocking the actions of IL-1 which is released into the body in response to stroke.

The researchers are not sure of the results at this stage as to how the reduction in inflammation will impact on clinical outcomes.

The study showed that when this drug was given an intravenous therapy, it reduced inflammation that occurred after the stroke and the subarachnoid hemorrhage.

In an another double-blind Manchester study, Kineret was tested against the placebo to check it's effectiveness in only stroke patients. A total of eighty participants in the study done at Salford's Greater Manchester Stroke Centre were given six doses of the drug or placebo for over three days. Within six hours of the stroke, the first dose was given. The Inflammatory markers were measured before treatment and during the whole study. "Though Strokes affect different people in different ways, for many people they have a devastating effect on their long-term health and wellbeing," said professor Craig Smith from The University of Manchester.

"Excessive inflammation after a stroke is known to be harmful and predicts a worse outcome in patients."

"We have shown that Kineret injections, started within six hours of stroke onset significantly reduces levels of inflammation in patients." added professor Smith.

"This study builds on evidence that IL-1Ra (Kineret) helps to reduce inflammation and brain damage in a wide range of stroke patients soon after a stroke. The drug can be given quickly, via injection or via a drip. This means that it can be used in different settings, for example, it could potentially be given in ambulances on the way to the hospital. The brain loses around 2 million brain cells every minute during a stroke, so this could provide a major step forward in the fast and effective treatment of stroke", said Hilary Reynolds, Executive Director of Strategy & Research at the Stroke Association.

More research needs to be done to understand whether Kineret could be an effective treatment for ischemic stroke alongside current treatments such as clot-busting drugs (thrombolysis).

This research team has also shown that Kineret can reduce inflammation and is safe in patients with bleeding around the brain (subarachnoid hemorrhage).

One more trail with 80 patients with intracerebral hemorrhage is going to be conducted sometime soon this year. This study will test if markers of inflammation are getting reduced by Kineret or not and if the test is safe in intracerebral hemorrhage.

Reference
  1. Craig J. Smith, Sharon Hulme, Andy Vail, Calvin Heal, Adrian R. Parry-Jones, Sylvia Scarth, Karen Hopkins, Margaret Hoadley, Stuart M. Allan, Nancy J. Rothwell, Stephen J. Hopkins, Pippa J. Tyrrell.SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke), Stroke (2018). https://doi.org/10.1161/STROKEAHA.118.020750


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Drug Toxicity Osteoarthritis Rheumatoid Arthritis Bell´s Palsy Oligoarthritis Spondylolisthesis Diet Lifestyle and Heart Disease Chemotherapy Mitral Valve Stenosis And Mitral Valve Replacement Chemotherapy Drugs 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive